Liver Transplantation in HIV-HCV Coinfected Patients A Case-Control Study

Autor: Castells, Lluis, Escartín, Alfredo, Bilbao, Itxarone, Len, Oscar, Allende, Helena, Vargas, Víctor, Ribera, Esteban, Lázaro, José-Luis, Bueno, Javier, Balsells, Joaquin, Esteban, Rafael, Pahissa, Albert, Margarit, Carlos
Zdroj: Transplantation; February 2007, Vol. 83 Issue: 3 p354-358, 5p
Abstrakt: Liver transplantation (LT) for hepatitis C virus (HCV)-associated cirrhosis in human immunodeficiency virus (HIV)-infected patients was compared with non-HIV patients. Nine patients with HIV-HCV coinfection were compared with patients transplanted before and after each HIV patient (control group). Immunosuppression consisted in tacrolimus with steroids or mycophenolate mofetil. Acute cellular rejection and three-year actuarial patient survival were respectively 44% and 87.5% in HIV group and 22% and 93.7% in the control group (PNS). Acute hepatitis C virus occurred earlier (2.3 vs. 4.3 months) and was more cholestatic (mean bilirubin: 10.8 vs. 1.6 mg/dL) in the HIV group. Eight (100%) HIV and nine (64.3%) control patients received antiviral treatment with pegylated interferon and ribavirin. One patient (11.1%) of the control group and one patient (20%) of the HIV group presented a sustained virologic response (PNS). Short- to midterm results of LT in HIV-HCV co-infected patients were excellent and similar to non-HIV patients.
Databáze: Supplemental Index